| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 74926 |
Re-cyc-DOTA-sst2-ANT复合物 |
97 |
h |
2024-12-19 |
| 74927 |
DOTA-SP DOTA-P物质(SP) |
105 |
h |
2024-12-19 |
| 74928 |
DOTA-MG45 DOTA偶联迷你胃泌素(MG45) |
100 |
h |
2024-12-19 |
| 74929 |
DOTA-甘露糖胺葡聚糖 DOTA-MADs |
84 |
h |
2024-12-19 |
| 74930 |
ICG-DOTA 大环配体DOTA修饰吲哚菁绿荧光染料 |
102 |
h |
2024-12-18 |
| 74931 |
DOTA-SSA 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)-生长抑素类似物(SSA) |
82 |
h |
2024-12-18 |
| 74932 |
DOTA螯合剂修饰[cPP(1-7) |
142 |
h |
2024-12-18 |
| 74933 |
DOTA-ALB-24 DOTA-4-(对碘苯基)丁酸酯-24 |
94 |
h |
2024-12-18 |
| 74934 |
DOTA-GGNle-CycMSH hex DOTA偶联新肽 |
110 |
h |
2024-12-18 |
| 74935 |
Zr-p-NO2Bn-DOTA异构体 锆-硝基苄基偶联DOTA螯合剂 |
106 |
h |
2024-12-18 |
| 74936 |
DOTA-PSMA-617 1,4,7,10-四氮杂环十五烷偶联PSMA-617 |
81 |
h |
2024-12-18 |
| 74937 |
DOTA-VAP-1 螯合剂DOTA偶联VAP-1靶向肽 |
145 |
h |
2024-12-18 |
| 74938 |
DOTA-GIP-C803 DOTA螯合剂缀合GIPC803肽 |
72 |
h |
2024-12-18 |
| 74939 |
DOTA-mPS 螯合剂DOTA修饰微米级聚苯乙烯 |
104 |
h |
2024-12-18 |
| 74940 |
DOTA-HBED-bisphosphonate DOTA-HBED-二膦酸盐 |
100 |
h |
2024-12-18 |
| 74941 |
CAS号：2226472-28-0 ，DBCO-PEG4-Val-Cit-PAB-PNP |
104 |
WYQ |
2024-12-18 |
| 74942 |
cas:2112738-09-5， Mal-PEG4-Val-Cit-PAB-PNP |
116 |
WYQ |
2024-12-18 |
| 74943 |
Mal-PEG8-Val-Cit-PAB-PNP，可以溶解于DCM、DMF、DMSO、THF等有机溶剂，以及水中。 |
121 |
WYQ |
2024-12-18 |
| 74944 |
Mal-PEG2-Val-Ala-PAB-PNP，含有马来酰亚胺（Mal）官能团、两个单元的聚乙二醇（PEG2）间隔物、缬氨酸（Val）和丙氨酸（Ala）的序列 |
75 |
WYQ |
2024-12-18 |
| 74945 |
Mal-PEG2-Val-Cit-PABA（CAS号：1662687-83-3） |
94 |
WYQ |
2024-12-18 |
| 74946 |
CAS号：1096584-62-1， Mal-Val-Cit-PAB-PNP |
71 |
WYQ |
2024-12-18 |
| 74947 |
Mal-amido-PEG2-Val-Cit-PAB-OH，马来酰亚胺-酰胺-二聚乙二醇-缬氨酸-瓜氨酸-PAB-羟基 |
70 |
WYQ |
2024-12-18 |
| 74948 |
CAS号：1949793-41-2 ，Mal-amido-PEG4-Val-Cit-PAB-OH |
82 |
WYQ |
2024-12-18 |
| 74949 |
DOTA-伊班膦酸 DOTA-IBA |
75 |
h |
2024-12-18 |
| 74950 |
FA-DOTA-PEG-PLGA 叶酸-DOTA-聚乙二醇-聚乳酸-羟基乙酸共聚物 |
83 |
h |
2024-12-18 |
| 74951 |
DOTA-泛素29-41 |
74 |
h |
2024-12-18 |
| 74952 |
cas:1226403-39-9，N-(2-(3,4-Difluorophenoxy)ethyl)-4-formylbenzamide |
77 |
kx |
2024-12-18 |
| 74953 |
Cu-64 DOTA-曲妥珠单抗 Cu-64-Herceptin |
122 |
h |
2024-12-18 |
| 74954 |
CAS号：2112738-13-1 ，Mal-amido-PEG2-Val-Cit-PAB-PNP |
80 |
WYQ |
2024-12-18 |
| 74955 |
CAS号：2055041-40-0 ， Azido-PEG1-Val-Cit-PAB-OH |
91 |
WYQ |
2024-12-18 |
| 74956 |
cas:1226006-55-8，N-(2-(3-Ethoxyphenoxy)ethyl)-4-formylbenzamide， ADC试剂 |
68 |
kx |
2024-12-18 |
| 74957 |
DOTA-LTVSPWY 双功能螯合剂DOTA偶联肽LTVSPWY |
74 |
h |
2024-12-18 |
| 74958 |
CAS号：2055024-65-0 ，Azido-PEG3-Val-Cit-PAB-OH |
79 |
WYQ |
2024-12-18 |
| 74959 |
DOTA-CCK-66 大环DOTA偶联CCK2R靶向化合物CCK-66 |
182 |
h |
2024-12-18 |
| 74960 |
cas:1228153-04-5，4-Formyl-N-(2-(naphthalen-2-yloxy)ethyl)benzamide |
105 |
kx |
2024-12-18 |
| 74961 |
抗DOTA IgG-scFv BsAb anti-DOTA IgG-scFv BsAb |
121 |
h |
2024-12-18 |
| 74962 |
cas:1226217-30-6，4-Formyl-N-(2-(4-isopropylphenoxy)ethyl)benzamide |
81 |
kx |
2024-12-18 |
| 74963 |
DOTA-rL-A9肽 DOTA偶联核定位序列(NLS)-移植的her 2-受体亲和肽 |
101 |
h |
2024-12-18 |
| 74964 |
cas:796073-59-1，2,5-Dioxopyrrolidin-1-yl 4-(methyldisulfanyl)pentanoate |
71 |
kx |
2024-12-18 |
| 74965 |
DOTA-E[c(RGDFK)]2 双功能螯合剂偶联的RGD多肽E[c(RGDfK)]2 |
76 |
h |
2024-12-18 |
| 74966 |
DBCO-C4-Val-Cit-PABC-PNP，分子式：C46H49N7O10 |
83 |
WYQ |
2024-12-18 |
| 74967 |
DBCO-(PEG)3-VC-PAB-MMAE，CAS号：57103-68-1 |
55 |
WYQ |
2024-12-18 |
| 74968 |
cas:1134280-65-1，2,5-Dioxopyrrolidin-1-yl 3-((2,4-difluorobenzyl)oxy)propanoate |
78 |
kx |
2024-12-18 |
| 74969 |
DBCO-PEG3-acetic-Val-Cit-PAB（二苯并环辛炔） |
84 |
WYQ |
2024-12-18 |
| 74970 |
cas:1824718-79-7，SPDH， ADC试剂 |
86 |
kx |
2024-12-18 |
齐岳微信公众号
官方微信
库存查询